Emily Sullivan - January 9, 2024 Pharma trade marks: 2023 EU case law round up As we enter 2024, we reflect on the lessons we have learned in 2023. The trade mark landscape has ...
Jamie Emerick - November 15, 2023 EU General Court provides guidance on consumer perception in the pharmaceutical industry Earlier this year, in March 2023, the European Union’s General Court provided some useful ...
Rebecca Anderson-Smith - September 1, 2023 Building an international Customs strategy for your pharma brand Counterfeit pharmaceuticals are a global problem and pose a significant threat to consumers and ...
Emily Sullivan - August 31, 2023 Understanding parallel import of pharmaceuticals in the EU – a quick guide to repackaging and relabelling of parallel imports for brand owners Parallel importing, the practice where third parties import branded goods already put on sale by ...
Karolina Fryzlewicz - August 25, 2023 Strategic Pharmaceutical Branding: when should you apply to register a trade mark if still undergoing clinical trials? Tying trade mark considerations into your drug development strategy can be a rather challenging ...
Rebecca Anderson-Smith - August 4, 2023 Court of Appeal confirms filing a trade mark cancellation action does not ‘stop the clock’ on acquiescence In our “Pharma trade marks: 2022 case law round up” (written towards the end of November 2022) we ...
Joe McAlary - March 28, 2023 Can parallel importers apply registered trade marks to previously unbranded products? Towards the back end of last year, the Court of Justice of the European Union (CJEU) gave a series ...
Rebecca Anderson-Smith - December 2, 2022 Pharma trade marks: 2022 case law round up As we enter December, and the year draws to a close, many trade mark practitioners and brand owners ...
Joe McAlary - December 2, 2022 Parallel imports of repackaged pharmaceutical products - clarification from recent CJEU rulings Recent case law of the Court of Justice of the European Union (CJEU) has clarified how the ...
Maria Hall - October 14, 2022 Robert Watson elected President of FICPI’s Study and Work Committee Partner Robert Watson was elected President of FICPI’s Study and Work Committee (Commission d'Etude ...
Rebecca Anderson-Smith - July 6, 2021 Non-traditional pharma trade marks: position marks In this final blog in our non-traditional pharma trade mark series, we will be examining position ...
Rebecca Anderson-Smith - May 27, 2021 Non-traditional pharma trade marks: sound, motion and multimedia marks Following on from our previous blog posts examining the role of shape marks and colour marks in the ...
Rebecca Anderson-Smith - April 21, 2021 Non-traditional pharma trade marks: colours Our previous blog post, Non-traditional pharma trade marks: shapes, explored the relevance of shape ...
Rebecca Anderson-Smith - March 23, 2021 Non-traditional pharma trade marks: shapes In our previous blog post 'Naming pharmaceuticals: considerations for choosing, clearing and ...
Rebecca Anderson-Smith - March 22, 2021 Pharma brands: what's in a name? Pinning down a new drug name that will both catch attention and clear regulatory hurdles requires ...
Rebecca Anderson-Smith - October 28, 2020 Naming pharmaceuticals: considerations for choosing, clearing and registering pharmaceutical brand names There are many different types of names you might see associated with a pharmaceutical product.
Rebecca Anderson-Smith - March 19, 2020 Parallel imports of pharmaceuticals – A UK trade mark perspective The UK parallel import licensing scheme lets a medicine authorised in another EU Member State be ...
